J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but ...

A University of Alberta research team has identified a DNA structure that activates the immune system in cancer cells that ...

Biomodal reports methylation sequencing is expanding the window for early detection.

Lung cancer cases are on the rise in non-smokers around the world, and air pollution could be an insidious, contributing ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

Researchers have uncovered new patterns of DNA damage associated with specific chemotherapy drugs to guide cancer treatment for less effects.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

"Just as scientists tracked COVID-19 outbreaks by detecting viral particles in wastewater, Fragle analyzes DNA fragments in blood to monitor cancer treatment response and detect relapse early ...